386 related articles for article (PubMed ID: 23123634)
21. A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission.
Linn YC; Yong HX; Niam M; Lim TJ; Chu S; Choong A; Chuah C; Goh YT; Hwang W; Loh Y; Ng HJ; Suck G; Chan M; Koh M
Cytotherapy; 2012 Aug; 14(7):851-9. PubMed ID: 22799277
[TBL] [Abstract][Full Text] [Related]
22. Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells.
Kim YJ; Lim J; Kang JS; Kim HM; Lee HK; Ryu HS; Kim JY; Hong JT; Kim Y; Han SB
Arch Pharm Res; 2010 Nov; 33(11):1789-95. PubMed ID: 21116782
[TBL] [Abstract][Full Text] [Related]
23. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
[TBL] [Abstract][Full Text] [Related]
24. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas.
Weng DS; Zhou J; Zhou QM; Zhao M; Wang QJ; Huang LX; Li YQ; Chen SP; Wu PH; Xia JC
J Immunother; 2008 Jan; 31(1):63-71. PubMed ID: 18157013
[TBL] [Abstract][Full Text] [Related]
25. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma.
Kim HM; Lim J; Yoon YD; Ahn JM; Kang JS; Lee K; Park SK; Jeong YJ; Kim JM; Han G; Yang KH; Kim YJ; Kim Y; Han SB
Int Immunopharmacol; 2007 Dec; 7(13):1793-801. PubMed ID: 17996690
[TBL] [Abstract][Full Text] [Related]
26. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of an automated closed fluid management device for processing expanded cytokine-induced killer cells to use in immunotherapy programs for cancer.
Giancola R; Olioso P; Di Riti M; Capone A; Contento A; Pompetti F; Iacone A
Transfusion; 2008 Apr; 48(4):629-39. PubMed ID: 18208417
[TBL] [Abstract][Full Text] [Related]
28. Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission.
Torelli GF; Guarini A; Palmieri G; Breccia M; Vitale A; Santoni A; Foa R
Br J Haematol; 2002 Feb; 116(2):299-307. PubMed ID: 11841430
[TBL] [Abstract][Full Text] [Related]
29. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells.
Jiang J; Xu N; Wu C; Deng H; Lu M; Li M; Xu B; Wu J; Wang R; Xu J; Nilsson-Ehle P
Anticancer Res; 2006; 26(3B):2237-42. PubMed ID: 16821594
[TBL] [Abstract][Full Text] [Related]
30. Implication of different effector mechanisms by cord blood-derived and peripheral blood-derived cytokine-induced killer cells to kill precursor B acute lymphoblastic leukemia cell lines.
Durrieu L; Lemieux W; Dieng MM; Fontaine F; Duval M; Le Deist F; Haddad E
Cytotherapy; 2014 Jun; 16(6):845-56. PubMed ID: 24529554
[TBL] [Abstract][Full Text] [Related]
31. Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation.
Introna M; Pievani A; Borleri G; Capelli C; Algarotti A; Micò C; Grassi A; Oldani E; Golay J; Rambaldi A
Biol Blood Marrow Transplant; 2010 Nov; 16(11):1603-7. PubMed ID: 20685246
[TBL] [Abstract][Full Text] [Related]
32. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer.
Sun Z; Shi L; Zhang H; Shao Y; Wang Y; Lin Y; Li X; Bai C
Clin Immunol; 2011 Jan; 138(1):23-32. PubMed ID: 21041120
[TBL] [Abstract][Full Text] [Related]
33. Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial.
Yang B; Lu XC; Yu RL; Chi XH; Liu Y; Wang Y; Dai HR; Zhu HL; Cai LL; Han WD
Hematol Oncol; 2012 Sep; 30(3):115-22. PubMed ID: 22972689
[TBL] [Abstract][Full Text] [Related]
34. Generation of T-cell lines to autologous acute myeloid leukemia cells by competitive limiting dilution culture of acute myeloid leukemia mononuclear cells.
Zhong RK; Lane TA; Ball ED
Exp Hematol; 2008 Apr; 36(4):486-94. PubMed ID: 18249062
[TBL] [Abstract][Full Text] [Related]
35. [Coculture of dendritic cell with cytokine-induced killer results in a significant increase in cytotoxic activity of CIK to tumor cells in vitro and in vivo].
Ge W; Li CH; Zhang W; Han Q; Deng WM; Chen L; You SG; Zhao CH
Zhonghua Xue Ye Xue Za Zhi; 2004 May; 25(5):277-80. PubMed ID: 15182535
[TBL] [Abstract][Full Text] [Related]
36. Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells.
Hongeng S; Petvises S; Worapongpaiboon S; Rerkamnuaychoke B; Pakakasama S; Jootar S
Int J Hematol; 2003 Feb; 77(2):175-9. PubMed ID: 12627854
[TBL] [Abstract][Full Text] [Related]
37. Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model.
Kim HM; Kang JS; Lim J; Kim JY; Kim YJ; Lee SJ; Song S; Hong JT; Kim Y; Han SB
Arch Pharm Res; 2009 May; 32(5):781-7. PubMed ID: 19471894
[TBL] [Abstract][Full Text] [Related]
38. Clinical study of autologous cytokine-induced killer cells for the treatment of elderly patients with diffuse large B-cell lymphoma.
Lu XC; Yang B; Yu RL; Chi XH; Tuo S; Tuo CW; Zhu HL; Wang Y; Jiang CG; Fu XB; Yang Y; Liu Y; Yao SQ; Dai HR; Cai L; Li BJ; Han WD
Cell Biochem Biophys; 2012 Jan; 62(1):257-65. PubMed ID: 21913005
[TBL] [Abstract][Full Text] [Related]
39. Human interferon-alpha increases the cytotoxic effect of CD56(+) cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines.
Durrieu L; Gregoire-Gauthier J; Dieng MM; Fontaine F; le Deist F; Haddad E
Cytotherapy; 2012 Nov; 14(10):1245-57. PubMed ID: 22974386
[TBL] [Abstract][Full Text] [Related]
40. Possibility of adoptive immunotherapy with peripheral blood-derived CD3⁻CD56+ and CD3+CD56+ cells for inducing antihepatocellular carcinoma and antihepatitis C virus activity.
Doskali M; Tanaka Y; Ohira M; Ishiyama K; Tashiro H; Chayama K; Ohdan H
J Immunother; 2011 Mar; 34(2):129-38. PubMed ID: 21304407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
